They are then infused back into the patient, with sometimes powerful results. Novartis’ CAR-T, Kymriah (tisagenlecleucel) was shown to be capable of noteworthy results, with a multi-centre ...

Novartis' CAR-T therapy Kymriah racked up back-to-back approvals in acute lymphoblastic leukaemia and large B-cell lymphoma a few years ago, but hasn't added to its label since.

In one of the largest cell and gene therapy funding rounds this year, the US company Arsenal Biosciences has secured $325 ...

Today we report on studies that might lead to a closer look at mammography findings involving clogged arteries. Calcium ...

Mammography: "Prior research has already suggested this type of association," study leader Hannah Daley of Drexel University ...

Novartis' Kymriah or Gilead Science's Tecartus or Yescarta. After a median follow-up of 21.7 months, 5.8% of patients developed a second primary malignancy. Among 1,253 participants in four ...

Novartis' Kymriah or Gilead Science's Tecartus or Yescarta. After a median follow-up of 21.7 months, 5.8% of patients developed a second primary malignancy. Among 1,253 participants in four ...

The frequency of second primary malignancies (SPMs) arising in cancer survivors following treatment with CAR T-cell therapy was statistically comparable to the frequency of SPMs following other ...

At Novartis, he led the U.S. Oncology business, overseeing flagship products such as Tasigna®, Gleevec®, and Kymriah®, and played a key role in integrating the GSK oncology portfolio.